The Uromigos
The Uromigos broadcasts the latest developments in genitourinary (GU) cancer. Hosted by Brian Rini, MD, an Ingram Professor of Medicine at Vanderbilt-Ingram Cancer Center, and Tom Powles, Director of Barts Cancer Centre and Professor of Genitourinary Oncology at Queen Mary University of London. The podcast covers research, treatments, and insights in the field of GU oncology.
Episodes
Episode 516: The Influence of Hypoxia on Response and Resistance in RCC
Ari Hakimi and Lyn Voung from MSKCC join Brian and Tom to discuss their recent Cancer Cell paper exploring the mechanistic impact of TKI-induced hypoxia on immune response in RCC.
Episode 515: PROTEUS - A Reflection on the Data and Controversies with Neha Vapiwala
Brian and Tom invite Neha Vapiwala, a Radiation Oncologist, to discuss areas of consensus and controversy from the PROTEUS trial of ADT +/- apalutamide in high-risk localized prostate cancer.
Episode 514: Artificial Intelligence in Cancer Drug Development
Travis Zack, CMO of Open Evidence, joins Brian and Tom to discuss the emergence of AI across the spectrum on cancer, drug development and application of data.
Episode 513: Trials and Tribulations of Investigator-initiated Research
Bishoy Faltas joins Brian and Tom to discuss his IIT in bladder cancer. The intended discussion of the trials turned into an insightful discussion on the challenges and learning opportunities of IITs.
Episode 512: ENZA-P Nature Medicine translational data
In our final episode recorded at APCCC, Louise Emmett joins us to discuss clinical results and mechanisms of PSMA upregulation by enzalutamide.
Episode 510: ADCs in Prostate Cancer
Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and future direcctions.
Episode 509: ASCO 2026 Review
This comprehensive podcast covers the latest advances in prostate, bladder, and kidney cancers from ASCO 2026, including new therapies, trial data, and practice-changing insights. Brian, Tom and Silke analyze recent studies, controversies, and future directions in GU oncology.
Episode 508: ASCO 2026 Plenary - PROTEUS: ADT +/- Apalutamide in high-risk Localized Prostate Cancer
Mary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about the landscape of high risk prostate cancer.
Episode 507: ASCO 2026 - TALAPRO-3
Neeraj Aggarwal joins the show to discuss the phase 3 TALAPRO-3 trial of talazoparib and enzlautamide in metastatic hormone-sensitive prostate cancer, focusing on trial design, efficacy, safety, and genetic subsets.
Episode 506: ASCO 2026 - How do we measure quality of life in GU patients?
This panel discussion podcast with Brian, Tom, Peter O'Donnell and Elizabeth Nally explores the complexities of measuring quality of life in cancer clinical trials, highlighting recent data, patient perspectives, and innovative approaches to assessment. Experts discuss the limitations of current tools, the importance of long-term follow-up, and future directions for integrating patient-centere
Episode 505 : ASCO 2026 - RAMPART
James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data contribute to the adjuvant RCC landscape.
Episode 504: ASCO 2026 - ADC Drug Development in Urothelial Cancer
This episode with Gopa Iyer from MSKCC explores the latest advances in antibody drug conjugates (ADCs) in urothelial cancer, including data from EV302, novel ADCs targeting Nectin-4, and sequencing strategies. Experts discuss efficacy, safety, biomarkers, and future directions in bladder cancer treatment.
Episode 499: APCCC 2026 - Radioligands in Prostate Cancer
This session features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in prostate cancer treatment. Gain a deep understanding of current practices, challenges, and future directions in radiopharmaceuticals.
Episode 503: ASCO 2026 Preview
Silke joins Brian and Tom to discuss what to look for in GU cancers at ASCO 2026
Episode 502: AUA 2026 and FDA bladder cancer meeting
In this episode, Brian and Tom engage with Ashish Kamat to discuss the recent FDA meeting focused on bladder cancer treatments, particularly the nuances between CIS and papillary disease. They explore the challenges of drug approvals, the importance of randomized trials, and the emerging data on Deltalimagene, a non-viral gene therapy. The conversation highlights the complexities of treatment opti
Episode 501: APCCC 2026 - Biochemically-relapsed Prostate cancer
Chuck Ryan from MSKCC joins us in Lugano for the final podcast from APCCC to talk about the ever-evolving space of BCR in prostate cancer.
Episode 500: RAS Inhibition in Pancreatic Cancer (yes this is the Uromigos podcast..)
Filippo Pietrantonio from the National Cancer Institute of Milan joins the podcast to discuss the latest developments in RAS targeting in GI cancers, focusing on the exciting data with daraxonrasib in pancreatic cancer ahead of the ASCO 2026 plenary phase 3 data. We discuss the RAS pathway, prior unsuccessful targeting efforts and nuances on response and resistance.
Episode 498: APCCC 2026 - mCRPC
This APCCC podcast with Elena Castro features a detailed discussion on recent advances and ongoing debates in the treatment of castrate resistant prostate cancer (CRPC), including the placement of lutetium, biomarker-driven therapy, and emerging treatment options.
Episode 497: Reflections on the capivasertib ODAC
This podcast features a detailed discussion on the recent ODAC meeting, focusing on the evaluation of capivasertib, an AKT inhibitor in metastatic hormone-sensitive prostate cancer. Experts analyze trial data, benefit-risk considerations, biomarker challenges, and regulatory perspectives.
Episode 496: APCCC 2026 - mHSPC Landscape
Rob Jones joins us in Lugano at the APCCC Meeting to discuss areas of consensus and controversy in the mHSPC landscape including de-escalation strategies.
Episode 495: APCCC 2026 - Locally-advanced Prostate Cancer
This episode with Piet Ost covers the latest insights from the APCCC conference in Lugano, focusing on locally advanced prostate cancer, biochemical relapse, and the role of PSMA PET imaging and biomarkers in treatment decisions.
Episode 494: Duration of EVP in Multiple Urothelial Cancer Settings / Paper of the Month PPARG Inverse Agonist
Matt Galsky joins the show to talk about duration of EVP in multiple bladder cancer settings. He also talks about his recent Nature Medicine manuscript on the PPARG inverse agonist in advanced bladder cancer.
Episode 493: The Role of Chemotherapy in mHSPC
In the world of prostate cancer treatment, chemotherapy's role, especially in metastatic hormone-sensitive cases, remains a topic of much discussion and evolving understanding. In this podcast, we delve into the insights shared during a recent conversation with Dr. Deepak Kilari, a GU Medical Oncologist, exploring the nuances of chemotherapy in this context. We discuss key trials, shifting def
Episode 492: Novel Biomarkers and Targets in Germ Cell Tumors
This podcast features Dr. Mike Glover from MDACC discussing recent advances in germ cell tumor research, focusing on novel biomarkers like microRNA and ctDNA, and emerging therapies targeting Claudin-6. The conversation explores how these innovations could transform diagnosis, prognosis, and treatment strategies.
Episode 490: Systemic Therapy Only in Patients wtih MIBC
Laura Bukavina, Tyler Stewart and Amanda Nizam join Brian and Tom to discuss and debate a new clinical trial exploring EVP in MIBC with omission of cystectomy of clinical CR patients
Episode 489: Live Podcast From EAU
Tom and Brian take the stage in London for a live podcast. With the help of several special guests from the audience, they discuss management of peri-operative therapy in bladder cancer (notably in patients who may refuse cystectomy) and also the emerging pembro plus belzutifan data in adjuvant RCC.
Episode 487: ASCO GU 2026 recap
Brian, Silke and Tom discusses the latest data and insights from ASCO GU 2026 across kidney, prostate, and bladder cancer, highlighting new therapies, trial results, and future directions in urologic oncology.
Episode 486: ctDNA and utDNA Data in Peri-operative Urothelial cancer
summaryThis episode explores the latest advances in circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA) in bladder cancer management. Experts discuss how these biomarkers are transforming perioperative decision-making, prognosis, and personalized treatment strategies.
Episode 485: ASCO GU 2026 - LITESPARK 011: Len/Belzu vs Cabo
This detailed discussion covers the latest phase three trial results in kidney cancer, focusing on LITESPARK 011: Belzutifan plus Lenvatnib versus Cabozantinib. Brian, Tom and Bob Motzer analyze efficacy, safety, and implications for treatment sequencing.
Episode 484: ASCO GU 2026 - LITESPARK 022: Adjuvant Pembro + Belzutifan in RCC
This in-depth discussion explores the latest advancements in adjuvant kidney cancer treatment, focusing on the recent phase 3 trial results of belzutifan combined with Pembrolizumab (LITESPARK-022), mechanistic insights, biomarker development, and future research directions.
Episode 482: ASCO GU 2026 - SUNRISE 2
The conversation revolves around the Sunrise 2 trial, a study investigating the efficacy of TAR-200 combined with cetrilimab versus traditional chemoradiotherapy in muscle-invasive bladder cancer. The discussion covers the study's design, patient population, results, and implications for future treatment strategies, emphasizing the importance of patient selection and the potential for TAR-200 in e
Episode 483: ASCO GU 2026 - KEYNOTE B15: Neoadjuvant EVP vs Gem/Cis in Cis-eligible MIBC
In this podcast , Brian, Tom and Matt Galsky discuss the B15 study data on neoadjuvant therapy for muscle invasive bladder cancer, focusing on the efficacy of EV Pembro compared to gem-cis. They explore event-free survival, overall survival, and the implications of treatment duration and individualization. The conversation also touches on the role of ctDNA in treatment decisions, alternative histo
Episode 480: ASCO GU 2026 - PEACE-3 and BRCAway Final OS Results
In this episode, Evan Yu discusses the latest prostate cancer data presented at ASCO GU, focusing on the final overall survival results of the PEACE 3 trial, the implications of crossing survival curves, and the evolving role of radioligand therapy and PARP inhibitors in prostate cancer treatment.
Episode 479: Does the Timing of IO Infusion Impact Clinical Outcomes? A Critical Analysis
This episode critically examines a recent Nature Medicine paper on the timing of immune therapy infusion in lung cancer, exploring the scientific plausibility, methodological concerns, and implications for future research. Tom, Brian and David McDermott debate the validity of the findings, the review process, and the need for rigorous prospective trials.
Episode 478: Prostate Cancer Working Group 4 (PCWG 4) criteria
SummaryThis Uromigos podcast delves into the evolution and significance of the Prostate Cancer Working Group criteria, highlighting the iterative process of developing guidelines that reflect the latest scientific evidence and clinical practices. The speakers discuss the new PCWG4 including new nomenclature, the role of imaging technologies like PSMA PET, and the importance of biomarkers and patie
Episode 476: ASCO GU 2026 Preview
In this podcast , the Uromigos discuss the upcoming ASCO GU conference. They delve into the latest research findings, including phase 3 trials, combination therapies, and the significance of biomarkers in treatment. The conversation highlights the importance of belzutifan in kidney cancer and explores the evolving landscape of prostate and bladder cancer treatments. The hosts also share their pred
Episode 475: Depth of Response and Overall Survival for IO-based Regimens in mRCC: Results of an FDA Analysis
In this Uromigos podcast episode, Brian and Tom engage with Elaine Chang from the FDA to discuss an analysis of depth of response as an indicator of survival in kidney cancer trials. They explore the FDA's data analysis process, the significance of tumor shrinkage, and the implications of their findings on treatment outcomes. The conversation delves into the limitations of current measurement
Episode 474: Uromigos Shorts - IO-refractory Urothelial Cancer
In this episode of the Uromigos podcast, Brian Rini, Tom Powles, and Karine Tawagi discuss the complexities of immunotherapy re-challenge in bladder cancer. They explore the current landscape, including the challenges of existing data, the importance of understanding patient responses, and the potential for future research in antibody-drug conjugates (ADCs). The conversation highlights the need fo
Episode 473: Uromigos Shorts - EMBARK and BCR Prostate Cancer
In this podcast, the Brian, Tm and David Einstein discuss the EMBARK study and its implications for patients with biochemically relapsed prostate cancer. They explore the criteria for high-risk patients, the role of PSMA PET imaging, and the findings related to metastasis-free survival and overall survival. The conversation also delves into treatment strategies, adverse events, and patient perspec
Episode 472: Uromigos Shorts - Variant Histology Bladder Cancer
This podcast discusses the significance of variant histology in urothelial cancer, emphasizing the need for tailored treatment approaches based on histological features. Experts David Aggen, Tom Powles and Brian Rini explore various variant histologies, their implications for treatment, and the challenges in managing mixed histology tumors. The conversation highlights the importance of expert path
Episode 471: Uromigos Shorts - ADCs and BiTEs in Prostate Cancer
In this podcast, Brian and Tom engage with Pedro Barata to discuss the emerging field of bispecific T cell engagers and antibody-drug conjugates (ADCs) in the treatment of prostate cancer. They explore the promising data surrounding these therapies, the challenges faced in clinical trials, and the implications of phase three studies. The discussion also touches on the comparative development of AD
Episode 470: Bladder Cancer Year in Review
Tom, Brian and Silke discuss the blockbuster 2025 for urothelial cancer
Episode 469: Prostate Cancer year in Review
Silke details the 2025 prostate cancer highlights
Episode 468: RCC Year in Review
Brian, Tom and Silke discuss the highlights of RCC for 2025
Episode 442: The History of ARPI Development in Prostate Cancer
Michael Morris from MSKCC joins us for an in-depth review of ARPI development across the spectrum of prostate caner
Episode 466: #UromigosLive 2025 - Novel Therapy in mRCC
Brian and Tom tag team moderate this session which covers combination data, VEGF/PD1 bispecifics, microbiome approaches, cellular therapy and enrichment strategies.
Episode 465: #UromigosLive 2025 - Adjuvant Therapy in RCC
Tom leads the panel discussion about this evolving space including the RAMPART data and the press release about pembro/belzu.
Episode 464: #UromigosLive 2025 - The Evolving Landscape of mHSPC
Brian moderates a panel of Chris Sweeney, Tanya Dorff, Mike Morris, Neeraj Aggarwal and Chuck Ryan as they discus and debate the mHSPC space with many treatment options.
Episode 459: #UromigosLive 2025 - Radioligands in Prostate Cancer
Brian leads a discussion of Rana McCay, Chris Sweeney and Michael Morris on the PSMAddition data and the landscape of radioligands in prostate cancer.
Episode 458: #UromigosLive 2025 - Mock ODAC
Brian takes the role of the FDA and we conduct a mock ODAC on the CREST and POTOMAC data
Episode 457: #UromigosLive 2025: ADCs in Bladder Cancer
Tom moderates Jun Guo, Matt Galsky, Michiel Van der Heidjen and Shilpa Gupta as they discuss this ever-expanding class of agents in bladder cancer.
Episode 456: #UromigosLive 2025: Peri-operative Therapy for Urothlial Cancer
The first session from UromigosLive 2025! In this episode, Tom moderates as Jonathan Rosenberg, Matt Galsky, Kala Sridhar and Josh Meeks discuss the peri-operative space and the impact of the neoadjuvant EVP and other data.
Episode 455: ESMO 2025 Urothelial Cancer Review
Tom and Brian discuss the bladder cancer highlights from ESMO 2025. Show throwing is discussed.
Episode 454: ESMO 2025 Prostate and Kidney Cancer Review
Silke, Tom and Brian discuss the prostate and RCC highlights from ESMO 2025
Episode 453: ESMO 2025 - IMvigor011
Alex Wyatt joins us to discuss Tom's IMvigor011 data and the field of ctDNA
Episode 452: ESMO 2025 - DV+ toripalimab in bladder cancer
Matt Galsky discusses the exciting Presidential session data from the Chinese phase 3 of DV+ toripalimab in advanced urothelial cancer.
Episode 451: ESMO 2025 - PSMAddition
Scott Tagawa discusses his ESMO Presidential presentation on Lu-PSMA-617 in patients with mHSPC
Episode 450: ESMO 2025 - CAPITELLO
Elena Castro describes the CAPITELLLO prostate cancer trial and her analysis from ESMO 2025
Episode 449: ESMO 2025 - ENZARAD
Paul Nguyen and Chris Sweeney double team the ENZARAD data and put it into context with other data including STAMPEDE
Episode 448: Neoadjuvant EV/Pembro in Cis-ineligible MIBC
Christof Vulsteke joins Brian and Tom to discuss his practice-changing data on neoadjuvant EVP in MIBC. More applause!!
Episode 447: ESMO 2025 - RAMPART
James Larkin joins to discuss adjuvant durva/treme vs observation in high risk resected RCC
Episode 446: ESMO 2025 - OPTIC and front-line RCC triplets
Cristina Rodriguez joins us to discuss her data on front-line triplets, and we also discuss the prospective RNAseq-based biomarker OPTIC study
Episode 445: ESMO 2025 - Systemic Checkpoint Inhibition plus BCG in NMIBC (POTOMAC and ALBAN)
Brad McGregor joins us on the heels of his #ESMO25 discussion of these important data in the NMIBC landscape.
Episode 444: ESMO 2025 Preview - Prostate and Renal Cancer
Silke joins us to discuss some important data being presented in prostate cancer. Brian and Tom also cover the RCC data at ESMO 2025
Episode 443: ESMO 2025 Bladder Cancer Preview
Tom and Brian preview the practice-changing bladder cancer data to be presented at ESMO 2025 in Berlin
Episode 441: The History of IO in Urothelial Cancer - Part 2
Jonathan Rosenberg returns to finish this two-part series on IO drug development in urothelial cancer
Episode 440: The History of IO in Urothelial Cancer - Part 1
Jonathan Rosenberg joins in this 2-part series on the history of IO-based therapy in Urothelial Cancer
Episode 439: Transcriptome Expression and Treatment Sensitivity in Prostate Cancer
Gert Attard joins the show to discuss his recent Cell publication looking at tumor transcriptome-wide expression classifiers in advanced prostate cancer.
Episode 438: The History of Testis Cancer Treatment
Christian Kollmannsberger joins us to walk through decades of advances in advanced testis cancer.
Episode 436: The History of IO in RCC - Part 2
We continue our conversation with Mike Atkins and David McDermott, discussing IO-based combination therapy in RCC.
Episode 435: The History of IO in RCC - Part 1
The fathers of IO therapy in RCC - Michael Atkins and David McDermott - join us to take a tour through IO development in RCC over the last 20 years.
Episode 434: IMPACT series - A Walk Through the History of VEGF TKI Development in RCC
Danny Heng joins to tour through VEGF TKI drug development from sorafenib to tivozanib and everything in between.
Episode 432: ASCO 2025 Rapid Oral Session RCC/Bladder Recap
Karie Runcie, MD joins us after chairing the ASCO 2025 rapid oral session to discuss the rcc/bladder presentations.
Episode 431: IMPACT series - Axel Bex on Impactful RCC Clinical Trials
Axel Bex joins the show to discuss trials that he thinks have impacted RCC. We also discuss consolidative approaches, neoadjuvant trials and what can impact an academic career.
Episode 430: Structured Exercise Improves DFS/OS after Adjuvant Therapy in Colorectal Cancer - Does This Apply to GU Cancers?
Chris Booth joins the show to discuss his recent NEJM paper that demonstrated significant DFS and OS improvements with a structured exercise program after adjuvant chemo in colorectal cancer. We discuss implications for GU and other malignancies.
Episode 428: ASCO 2025 Recap
Brian, Tom and Silke discuss their highlights form ASCO 2025
Episode 427: Emerging Data in Non-muscle Invasive Bladder Cancer (NMIBC)
Josh Meeks joins us to give stellar overview of the emerging data in this space. We also discuss the recent ODAC ruling for lower risk patients.
Episode 426 - ASCO 2025: AMPLITUDE Phase 3 of PARPi in mHSPC
Gert Attard joins us to discuss this practice-changing data and the highlight of ASCO 2025
Episode 425: ASCO 2025 - AI-enabled selection of patients for benefit of ADT + ARPI
Nick James discusses intriguing data from STAMPEDE to us AI to analyze pathology slides to predict benefit from ADT + abiraterone
Episode 424: ASCO 2025 - Emergency podcast on the prostate rapid oral session
Jorge Garcia joins us to discuss the process of selecting abstracts for oral presentation and select highlights from this session.
Recommended
Pintastic® Pinterest Podcast
Learn 50 English Phrases While You Sleep | Everyday English Phrases & Vocabulary
The Daily
The Joe Rogan Experience
World News Tonight with David Muir
Talk About Talk - Executive & Leadership Communication Skills
This Past Weekend w/ Theo Von
Stand In The Circle
Conspiracy Files with Paige Carter
Learn English B1 with Daily News | English Listening Practice
Bad Friends
The Swerve Podcast: Obscure Topics | Conspiracy Theories
